Article

Valproic acid enhances gene expression from viral gene transfer vectors.

Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Ave., Box 672 (Room 3-9609), Rochester, NY 14642, USA.
Journal of Virological Methods (Impact Factor: 1.88). 05/2005; 125(1):23-33. DOI: 10.1016/j.jviromet.2004.11.023
Source: PubMed

ABSTRACT Viral vectors represent an efficient delivery method for in vitro and in vivo gene transfer, and their utility may be further enhanced through the use of pharmacologic agents that increase gene expression. Here, we demonstrate that valproic acid (VPA), a drug which is widely used for the treatment of epilepsy and mood disorders, enhances and prolongs expression of exogenous genes in cells transduced with various gene transfer agents, including adenovirus, adeno-associated virus and herpesvirus vectors. This effect occurs in a wide range of cell types, including both primary cells and cell lines, and appears to be associated with VPA's ability to function as a histone deacetylase inhibitor (HDACi). VPA treatment also enhanced adenovirally-vectored expression of a luciferase reporter gene in mice, as demonstrated by in vivo imaging. VPA was also less cytotoxic than a commonly used HDAC inhibitor, TSA, suggesting its use as a safer alternative. Taken together, these results suggest that VPA treatment may represent a useful approach to various gene transfer approaches in which enhanced transgene expression is desirable.

0 Bookmarks
 · 
130 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Virus vector-mediated gene transfer has been developed as a treatment for cystic fibrosis (CF) airway disease, a lethal inherited disorder caused by somatic mutations in the cystic fibrosis transmembrane conductance regulator gene. The pathological proinflammatory environment of CF as well as the naïve and adaptive immunity induced by the virus vector itself limits the effectiveness of gene therapy for CF airway. Here, we report the use of an HDAC inhibitor, valproic acid (VPA), to enhance the activity of the regulatory T cells (Treg) and to improve the expression of virus vector-mediated gene transfer to the respiratory epithelium. Our study demonstrates the potential utility of VPA, a drug used for over 50 years in humans as an anticonvulsant and mood-stabilizer, in controlling inflammation and improving the efficacy of gene transfer in CF airway.Gene Therapy advance online publication, 2 January 2014; doi:10.1038/gt.2013.78.
    Gene therapy 01/2014; 21(2). DOI:10.1038/gt.2013.78 · 4.75 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: Varicella zoster virus (VZV) is the causative agent of varicella (chicken pox) and herpes zoster (shingles). After primary infection, the virus remains latent in sensory ganglia, and reactivates upon weakening of the cellular immune system due to various conditions, erupting from sensory neurons and infecting the corresponding skin tissue. The current varicella vaccine (v-Oka) is highly attenuated in the skin, yet retains its neurovirulence and may reactivate and damage sensory neurons. The reactivation is sometimes associated with postherpetic neuralgia (PHN), a severe pain along the affected sensory nerves that can linger for years, even after the herpetic rash resolves. In addition to the older population that develops a secondary infection resulting in herpes zoster, childhood breakthrough herpes zoster affects a small population of vaccinated children. There is a great need for a neuro-attenuated vaccine that would prevent not only the varicella manifestation, but, more importantly, any establishment of latency, and therefore herpes zoster. The development of a genetically-defined live-attenuated VZV vaccine that prevents neuronal and latent infection, in addition to primary varicella, is imperative for eventual eradication of VZV, and, if fully understood, has vast implications for many related herpesviruses and other viruses with similar pathogenic mechanisms.
    Virologica Sinica 10/2014; 29(5):265-273. DOI:10.1007/s12250-014-3516-9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Varicella-zoster virus (VZV) is a herpesvirus that is the causative agent of chickenpox and herpes zoster. The virus manifests as chickenpox upon primary infection, establishes latency in the sensory neurons, and can later reactivate as herpes zoster when the immune system is compromised. Although the v-Oka vaccine has been introduced to most children worldwide, the virus remains neurovirulent and is thus still able to reactivate and cause herpes zoster. Knowledge about VZV pathogenesis has been limited due to its highly cell-associated nature in culture, difficulty in generating recombinant viruses, and obstacles in in vivo viral pathogenesis studies. However, a combination of new approaches has made it possible to functionally profile the entire VZV genome, screen for tissue tropic factors, and analyze recombinant virus replication and pathogenesis in vivo. These approaches include the bacterial artificial chromosome technology for generating recombinant VZV, the humanized mouse model for studying viral tropism and pathogenesis in vivo, and a bioluminescence marker for monitoring viral growth in all models. From these recombinant virus studies, open reading frame 7 of the VZV genome was revealed to be a novel skin- and neurotropic factor. In addition, studies of the closely related Simian Varicella Virus and other VZV pathogenic studies in conjunction with genetic analyses of the entire VZV genome will not only lead to a better understanding of VZV pathogenesis, but also contribute to the development of a safer, more effective neuroattenuated vaccine candidate.
    Journal of Antivirals and Antiretrovirals 05/2013; 5:62-71. DOI:10.4172/jaa.1000065